 After stumbling throughout much of 2021 and early 2022 to meet analyst expectations, INFU has righted the ship and looks to have a strong back half of 2022 in store. Investors seemed to have been spooked by a delay in finalizing a contract with GE Healthcare, but the now-revealed details of the situation are extremely bullish. 